Meta-analysis on peginterferon plus ribavirin in treatment of hepatitis C virus genotype 1 or 4 infection in HIV patients.
- Author:
Si-Hai ZHAO
1
;
En-Qi LIU
;
Da-Xin CHENG
;
Xin XUE
;
Yong-Lie CHU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antiviral Agents; administration & dosage; Drug Therapy, Combination; Female; Genotype; HIV Infections; complications; drug therapy; immunology; Hepacivirus; classification; genetics; Hepatitis C, Chronic; complications; drug therapy; virology; Humans; Interferon-alpha; administration & dosage; Male; Polyethylene Glycols; administration & dosage; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; administration & dosage
- From: Journal of Zhejiang University. Medical sciences 2009;38(3):315-319
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo perform a Meta-analysis on peginterferon with interferon in treatment of HIV patients coinfected with refractory genotype HCV.
METHODSA literature search of Medline was conducted to identify eligible randomized controlled trials. Meta analysis was conducted to evaluate peginterferon and interferon in treatment of coinfected HCV genotype 1 or 4 in HIV patients.
RESULTSix trials of 88 matched the selection criteria. Total 1,131 patients with coinfection of HCV genotype 1 or 4 and HIV were included. Sustain viral response was higher in patients treated with peginterferon plus ribavirin compared with that of interferon plus ribavirin (26 % compared with 8 %) or peginterferon alone (26 % compared with 13 %). Severe adverse effects and withdrawal rates were similar for patients treated with peginterferon and patients treated with interferon.
CONCLUSIONPeginterferon plus ribavirin in treatment of patients with coinfection of genotype 1 or 4 HCV and HIV can achieve higher sustain viral response and the likelihoods of serious adverse effects and withdrawal rates are similar to other therapies.
